Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

As the population ages, brain pathologies such as neurodegenerative diseases and brain
cancer increase their incidence, being the need to find successful treatments of upmost …

Object Non-small lung cancer (NSCLC), with a poor 5-year survival rate (16%), is the major
type of lung cancer. Metastasis has been identified as the main factor that leads to NSCLC …

High drug resistance, poor water solubility, short half-life, and low local drug concentration
are obstacles for successful delivery of chemotherapeutic drugs for lung cancer. A new …

Abstract Background Circular RNAs (circRNAs), a subgroup of non-coding RNAs, are
recognized as pivotal mediators in various types of cancers. CircRNA_0000284 …

Non‐small cell lung cancer (NSCLC) is the commonest malignancy with high death rate
around the world. LncRNA metastasis‐associated lung adenocarcinoma transcript 1 …

Molecular subtype classification represents a challenging field in lung cancer diagnosis.
Although different methods have been proposed for biomarker selection, efficient …

Abstract Objective Alpha-1, 3-mannosyltransferase (ALG3) is an oncoprotein associated
with multiple malignancies. We aimed to investigate the role and potential mechanisms of …

In an attempt to identify small molecules for targeted therapy of non-small cell lung
carcinoma (NSCLC) and prostate cancer (PCa), new arylidene indanones (1–10) were …

RNA interference has emerged as a powerful strategy in cancer therapy because it allows
silencing of specific genes associated with tumor progression and resistance. Mad2 is an …